Distributed and Lightweight Meta-heuristic Optimization method for Complex Problems

The world is becoming more prominent and more complex every day. The resources are limited and efficiently use them is one of the most requirement. Finding an Efficient and optimal solution in complex problems needs to practical methods. During the last decades, several optimization approaches have been presented that they can apply to different optimization problems, and they can achieve different performance on various problems. Different parameters can have a significant effect on the results, such as the type of search spaces. Between the main categories of optimization methods (deterministic and stochastic methods), stochastic optimization methods work more efficient on big complex problems than deterministic methods. But in highly complex problems, stochastic optimization methods also have some issues, such as execution time, convergence to local optimum, incompatible with distributed systems, and dependence on the type of search spaces. Therefore this thesis presents a distributed and lightweight metaheuristic optimization method (MICGA) for complex problems focusing on four main tracks. 1) The primary goal is to improve the execution time by MICGA. 2) The proposed method increases the stability and reliability of the results by using the multi-population strategy in the second track. 3) MICGA is compatible with distributed systems. 4) Finally, MICGA is applied to the different type of optimization problems with other kinds of search spaces (continuous, discrete and order based optimization problems). MICGA has been compared with other efficient optimization approaches. The results show the proposed work has been achieved enough improvement on the main issues of the stochastic methods that are mentioned before.Maailmasta on päivä päivältä tulossa yhä monimutkaisempi. Resurssit ovat rajalliset, ja siksi niiden tehokas käyttö on erittäin tärkeää. Tehokkaan ja optimaalisen ratkaisun löytäminen monimutkaisiin ongelmiin vaatii tehokkaita käytännön menetelmiä. Viime vuosikymmenien aikana on ehdotettu useita optimointimenetelmiä, joilla jokaisella on vahvuutensa ja heikkoutensa suorituskyvyn ja tarkkuuden suhteen erityyppisten ongelmien ratkaisemisessa. Parametreilla, kuten hakuavaruuden tyypillä, voi olla merkittävä vaikutus tuloksiin. Optimointimenetelmien pääryhmistä (deterministiset ja stokastiset menetelmät) stokastinen optimointi toimii suurissa monimutkaisissa ongelmissa tehokkaammin kuin deterministinen optimointi. Erittäin monimutkaisissa ongelmissa stokastisilla optimointimenetelmillä on kuitenkin myös joitain ongelmia, kuten korkeat suoritusajat, päätyminen paikallisiin optimipisteisiin, yhteensopimattomuus hajautetun toteutuksen kanssa ja riippuvuus hakuavaruuden tyypistä. Tämä opinnäytetyö esittelee hajautetun ja kevyen metaheuristisen optimointimenetelmän (MICGA) monimutkaisille ongelmille keskittyen neljään päätavoitteeseen: 1) Ensisijaisena tavoitteena on pienentää suoritusaikaa MICGA:n avulla. 2) Lisäksi ehdotettu menetelmä lisää tulosten vakautta ja luotettavuutta käyttämällä monipopulaatiostrategiaa. 3) MICGA tukee hajautettua toteutusta. 4) Lopuksi MICGA-menetelmää sovelletaan erilaisiin optimointiongelmiin, jotka edustavat erityyppisiä hakuavaruuksia (jatkuvat, diskreetit ja järjestykseen perustuvat optimointiongelmat). Työssä MICGA-menetelmää verrataan muihin tehokkaisiin optimointimenetelmiin. Tulokset osoittavat, että ehdotetulla menetelmällä saavutetaan selkeitä parannuksia yllä mainittuihin stokastisten menetelmien pääongelmiin liittyen

Survey of Recycled Nano Magnetic Particle in Benzene Removal from Aqueous Solution

The removal of benzene, a hazardous monoaromatic compound, from aqueous solution by recycled nano magnetic particle (NM) Fe3O4 in batch condition was evaluated. Regeneration studies verified that the benzene adsorbed by the NM could be easily desorbed by temperature. So that the benzene removal efficiency was 98.7 % for raw NM, 97.8 % for first recycled NM and 97.4 percent for second recycled NM. It is expected that the Fe3O4 nanoparticles with fine grain size (20-30 nm) will be used as one of effective, convenient and low-costing methods for removal and recovery of benzene from water and wastewater. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/3559

Concepts and Clinical Applications of Intraoral 3D Scanning in the Management of Patients with Orofacial Clefts

Digital workflow in the dental is on the brink of completely replacing the traditional workflow. This opened the frontier for the introduction of intraoral scanners (IOS). In the craniofacial field, IOS has proven its applicability in various procedures with highly promising results. This includes comprehensive diagnosis of patients with orofacial clefts and custom-made treatment planning of challenging cases as well as its use in nasoalveolar molding (NAM) therapy. IOS also opened the horizon to the advanced digital workflow required for appliances design, manufacturing, and virtual surgical planning. IOS offer various advantages that decrease the time, effort for both the patients, their families and care providers. IOS adopt different optical technologies what aim for precise recording of a three-dimensional (3D) object. This chapter aims to provide a comprehensive review of the use of intraoral scanners in the craniofacial field

Improving motion safety and efficiency of intelligent autonomous swarm of drones

Interest is growing in the use of autonomous swarms of drones in various mission-physical applications such as surveillance, intelligent monitoring, and rescue operations. Swarm systems should fulfill safety and efficiency constraints in order to guarantee dependable operations. To maximize motion safety, we should design the swarm system in such a way that drones do not collide with each other and/or other objects in the operating environment. On other hand, to ensure that the drones have sufficient resources to complete the required task reliably, we should also achieve efficiency while implementing the mission, by minimizing the travelling distance of the drones. In this paper, we propose a novel integrated approach that maximizes motion safety and efficiency while planning and controlling the operation of the swarm of drones. To achieve this goal, we propose a novel parallel evolutionary-based swarm mission planning algorithm. The evolutionary computing allows us to plan and optimize the routes of the drones at the run-time to maximize safety while minimizing travelling distance as the efficiency objective. In order to fulfill the defined constraints efficiently, our solution promotes a holistic approach that considers the whole design process from the definition of formal requirements through the software development. The results of benchmarking demonstrate that our approach improves the route efficiency by up to 10% route efficiency without any crashes in controlling swarms compared to state-of-the-art solutions. </p

Bayesian Policy Reuse

A long-lived autonomous agent should be able to respond online to novel instances of tasks from a familiar domain. Acting online requires 'fast' responses, in terms of rapid convergence, especially when the task instance has a short duration, such as in applications involving interactions with humans. These requirements can be problematic for many established methods for learning to act. In domains where the agent knows that the task instance is drawn from a family of related tasks, albeit without access to the label of any given instance, it can choose to act through a process of policy reuse from a library, rather than policy learning from scratch. In policy reuse, the agent has prior knowledge of the class of tasks in the form of a library of policies that were learnt from sample task instances during an offline training phase. We formalise the problem of policy reuse, and present an algorithm for efficiently responding to a novel task instance by reusing a policy from the library of existing policies, where the choice is based on observed 'signals' which correlate to policy performance. We achieve this by posing the problem as a Bayesian choice problem with a corresponding notion of an optimal response, but the computation of that response is in many cases intractable. Therefore, to reduce the computation cost of the posterior, we follow a Bayesian optimisation approach and define a set of policy selection functions, which balance exploration in the policy library against exploitation of previously tried policies, together with a model of expected performance of the policy library on their corresponding task instances. We validate our method in several simulated domains of interactive, short-duration episodic tasks, showing rapid convergence in unknown task variations.Comment: 32 pages, submitted to the Machine Learning Journa

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

Background: Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. Methods: This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Findings: Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p < 0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p < 0·001). Interpretation: Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication